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Abstract
Introduction: The improved survival of children with brain tumors has increased concerns about
treatment-related sequelae. Growth hormone deficiency is frequently observed after craniospinal
irradiation for medulloblastoma. It has been widely reported that growth hormone replacement
therapy does not increase the risk of second tumors, but there are reports in the literature of
growth hormone, and its downstream mediator insulin-like Growth Factor 1, having an important
proinflammatory action. There are few reports, however, on the "in-vivo" induction of edema and
symptomatic inflammatory lesions during replacement therapy.
Case presentation: We report the case of a 7-year-old girl treated for metastatic
medulloblastoma who developed growth hormone deficiency 2 years after oncological treatment.
Three months after replacement therapy, magnetic resonance imaging showed exacerbation of her
brain edema, which was already present after oncological treatment. We consequently suspended
the growth hormone until a new magnetic resonance image obtained 3 months later documented
a reduction of the inflammatory areas. We then re-introduced somatotropin at lower doses with
no further increase in brain edema in subsequent radiological controls.
Conclusion: This case and its iconography suggest a strong association between growth hormone
administration and the exacerbation of inflammatory reactions within the tumor bed. Replacement
therapy should be carefully monitored in this particular subset of patients.
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Introduction
Survival rates for patients with malignant pediatric brain
tumors have remarkably improved in recent years; the 5-
year relative survival probability for all brain malignancies
combined being approximately 69%, depending on the
pathophysiologic and morphologic characteristics for
children diagnosed in 1992 or later [1].
Due to this improvement, more attention is being focused
on the possible sequelae of oncological treatments (sur-
gery, chemotherapy and radiotherapy), among which
endocrinopathies are most frequently observed in
patients treated for central nervous system (CNS) tumors
with growth-hormone deficit (GHD) which is often
observed after irradiation. In particular, craniospinal irra-
diation for medulloblastoma commonly leads to GHD
(67% at 10 years after cranial irradiation greater than 24
Gy, 80% when greater than 30 Gy) and primary or mixed
hypothyroidism. In fact, irradiation of the hypothalamic-
pituitary axis causes a characteristic pattern of hormone
loss: growth hormone (GH) is usually the first to be
affected, followed by the gonadotrophins, ACTH and
TSH.
In the past, there was much concern about whether GH
therapy might increase cancer risk, but it has now been
established that GH treatment does not increase the rate
of tumor recurrence in patients previously treated for pri-
mary CNS lesions [2,3], and recent guidelines recom-
mend starting GH therapy a year after the end of the
oncological treatment if there is no evidence for further
tumor growth.
In addition to the oncological safety of GH, there are
reports that GH and its downstream mediator, insulin-
like Growth Factor 1 (IGF-1), have an important proin-
flammatory action [4-8]. A recent study by Pagani et al.
emphasizes that the production of proinflammatory
cytokines by the peripheral blood mononuclear cells is
lower in GH-deficient children than in healthy, age-
matched individuals, and that cytokine production is sig-
nificantly increased after 3 months of GH therapy [4].
Another study on the relationship between GH and brain
edema in rat brain freeze-injury models [5] revealed that
GH crosses the blood-brain barrier, finding a considerable
amount of GH receptors whose density is higher in the
choroid plexus, hypothalamus, hippocampus, pituitary
region, and spinal cord [6]. Moreover, GH administration
affects the concentrations of several neurotransmitters in
the cerebrospinal fluid and is probably related to post-
injury edema [6]. Further interactions between GH and/or
IGF-1 with the immune-inflammatory system have been
documented in the literature. For example, both GH and
IGF-1 increase the bactericidal capacity of human poly-
morphonuclear neutrophils via intracellular reactive oxy-
gen intermediaries, as well as increasing their
complement receptor expression [7]. Moreover, GH has a
proinflammatory activity also modulating several vascular
growth factors; IGF-1 correlates with angiogenin levels in
particular, stimulating endothelial cell proliferation as
well as collagen synthesis, fibroblasts, and vascular
smooth muscle cells [8].
GH replacement therapy in patients previously treated for
CNS tumors is subject not only to oncological assess-
ments, but also to auxological and endocrinological
parameters (growth failure, IGF-1 levels, pituitary defi-
ciencies, skeletal growth), and to the results of arginine
and/or clonidine challenges.
Case presentation
We report the case of a 7-year-old girl with metastatic
medulloblastoma (T3b M1 according to the Chang stag-
ing system) diagnosed as a result of an epileptic seizure
after 3 months of headache. Brain MRI in July 2000
revealed a mass in the posterior fossa, in the midline cer-
ebellum next to the fourth ventricle and vermis, causing
hydrocephalus and an initial herniation of the cerebellar
tonsils. At the end of July, she underwent a macroscopi-
cally complete resection of a 3 × 3 cm nodule filling the
fourth ventricle and attached to its lateral recesses. The
final histologic diagnosis was classic medulloblastoma.
A postoperative cerebral and spinal MRI in August 2000
revealed an ambiguous neoplastic residue close to the sur-
gical cavity, jutting out into the fourth ventricle, and
malignant neoplastic cells were found in the cerebrospi-
nal fluid.
From August 2000 to March 2001, the girl was treated
according to our institutional protocol for metastatic
medulloblastoma/PNET in children over 3 years of age,
which included sequential high-dose chemotherapy, radi-
otherapy, and myeloblative-dose chemotherapy with
autologous hemopoietic stem cell rescue [9]. The protocol
was partially modified omitting two scheduled vincristine
administrations due to intestinal toxicity after the first
course.
Hyperfractionated accelerated radiotherapy was adminis-
tered from November to December 2000, scheduled in
two daily 1.3 Gy fractions 6 hours apart, 5 days a week for
a total dose of 31.2 Gy to the craniospinal axis plus a
boost to the posterior fossa using a 1.5 Gy fractionation
twice a day to give a total dose of 59.7 Gy.
Diagnostic lumbar puncture before radiotherapy still doc-
umented malignant neoplastic cells, while lumbar punc-
ture and MRI after radiotherapy and between the twoJournal of Medical Case Reports 2009, 3:17 http://www.jmedicalcasereports.com/content/3/1/17
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myeloablative courses were both negative, with the latter
showing only surgical sequelae.
In June 2001, our patient started the follow-up program
with routine MRI and outpatient visits. In September
2001, MRI showed multiple focal contrast-enhanced areas
in the right thalamus, brainstem, and cerebellum, inter-
preted as iatrogenic alterations. A spectrum MRI con-
firmed their necrotic and treatment-related nature. These
lesions had increased in number in the MRI of December
2001, and they appeared more strongly gadolinium-
enhanced in subsequent images in February and April
2002. Cortisone therapy was administered from January
2002, starting with 6 mg/day. It was then progressively
tapered off, but the neurological signs became worse, with
cervical pain and frontal headache, so it was re-introduced
from March to July 2002.
In March 2002, a year after ending the oncological treat-
ment, an endocrinologist assessed the girl. At 8 years and
4 months old, her growth characteristics were: height 119
cm (3rd percentile), growth target 160 cm (25th percen-
tile), growth rate 0 cm per year, and basal IGF-1 below the
3rd percentile. Since her growth had not recovered, GH
replacement therapy was started after an arginine chal-
lenge in February 2004, administering somatotropin at a
dosage of 5 mg per week (15 UI, 0.16 mg/Kg per week).
In May 2004 (3 months after starting somatotropin), MRI
showed a clear progression of the enhanced lesions dis-
tributed along the occipital horn of the right lateral ventri-
cle and the peritrigonal region. The main finding was
perifocal edema, already seen at previous follow-up scans
but now extending further, to the posterior half of the
right hemisphere and in contact with the basal nuclei and
the thalamus. There was no evidence of recurrent disease
in the posterior fossa. The girl also reported headache and
visual impairment.
Relationship between somatotropin administration, MRI, clinical outcome, and steroid administration Figure 1
Relationship between somatotropin administration, MRI, clinical outcome, and steroid administration. Growth 
hormone administration was related to both MRI changes and a worse clinical performance. Dexamethasone administration 
produced no amelioration, either clinical or visible in the MRI. This was achieved instead by first suspending somatotropin, then 
restoring it at lower doses.
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Cortisone therapy was administered again, with no
improvement in the visual impairment or MRI findings.
Due to the latter, and the possible proinflammatory activ-
ity of GH, somatotropin was discontinued in June 2004.
Subsequent MRIs in September 2004 (3 months after sus-
pending somatotropin) and January 2005 (after 7 months
without somatotropin) showed a remarkable reduction of
the inflammatory areas both in the supratentorial region
and in the posterior fossa; the visual impairment had also
improved after suspending GH. In March 2005, we intro-
duced somatotropin again at lower doses (3 mg a week)
with no evidence of further edema in the post-therapy
alterations at subsequent MRIs in November 2005, June
2006, December 2006, July 2007, and March 2008 (Fig-
ures 1 and 2). No recurrent disease was documented by
these MRI studies, and the girl is currently in continuous
complete response.
Iconography strongly suggests an association between growth hormone administration and proinflammatory activity Figure 2
Iconography strongly suggests an association between growth hormone administration and proinflammatory 
activity. Axial MRI images immediately before administering growth hormone, after 3 months of growth hormone administra-
tion, 3 months after suspending growth hormone, and after 15 months of lower-dose administration of growth hormone. The 
areas of focal enhancement in the images taken before the therapy with growth hormone reveal inflammation and necrosis, an 
expression of post-therapy alterations. After 3 months of growth hormone therapy, the main finding is an increase in the peri-
focal edema occupying the posterior half of the right hemisphere, which decreased after suspending growth hormone. After 15 
months of low-dose administration of growth hormone, there is no evidence of further edema in the post-therapy radiological 
alterations.
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Conclusion
GH replacement therapy has proved effective in amelio-
rating growth impairment and quality of life, as evaluated
by both health- and psychological well-being tools. If GH
replacement is continued even after the final statural
growth has been achieved, it also seems to have positive
effects on somatic and skeletal maturation [2,3].
The experience we describe in this case report is significant
because many reports document the safety of GH replace-
ment therapy in terms of tumor progression, recurrence,
or development of secondary neoplasms, but few have
documented MRI changes and related symptoms due to
an exacerbation of any inflammatory parenchymal
lesions while on GH replacement therapy.
Moreover, the improved tools available for treating CNS
tumors (including radiotherapy and myeloablative chem-
otherapy with autologous stem cell transplantation) have
made it more difficult to obtain a differential diagnosis on
MRI findings because it is not clear how these therapeutic
measures and their late effects might affect the radiologi-
cal process [10]. The case reported here, and the related
iconography, are strongly suggestive of a close association
between GH administration and proinflammatory activ-
ity; although more evidence is needed to support our
observations.
This case also suggests that GH replacement therapy
should be delivered with caution and should be closely
monitored in patients previously treated for CNS malig-
nancies.
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